Health and Healthcare
Cell Therapeutics, Ready To Tap Financing (CTIC)
Published:
Cell Therapeutics (NASDAQ: CTIC) has filed an open mixed securities shelf registration for up to $150 million. This will allow it to sell debt securities, common stock, preferred stock, and warrants.
Last Tuesday, the company announced progress in beginning Phase III testing for its non-Hodgkin’s lymphoma treatment. Friday, the company filed its annual report.
Shares have showed no reaction to the filing, with a 0% change, sitting at $0.66. The 52-week range is $0.47 to $7.56 and its current market cap is only $62.5 million.
Rachel Lopez
March 31, 2008
Take This Retirement Quiz To Get Matched With An Advisor Now (Sponsored)
Are you ready for retirement? Planning for retirement can be overwhelming, that’s why it could be a good idea to speak to a fiduciary financial advisor about your goals today.
Start by taking this retirement quiz right here from SmartAsset that will match you with up to 3 financial advisors that serve your area and beyond in 5 minutes. Smart Asset is now matching over 50,000 people a month.
Click here now to get started.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
